Novel Chemical Series

About Gain Therapeutics

Gain Therapeutics is a clinical-stage biotech leveraging its proprietary Magellan™ platform to discover novel allosteric small molecule therapies for disorders with high unmet medical need. Founded in 2017, the company's lead program, GT-02287, is a best-in-class candidate for GBA-Parkinson's disease currently in Phase 1 clinical studies. Its strategy focuses on modulating protein function through stabilization, destabilization, or degradation, moving beyond simple inhibition to address the root cause of complex diseases.

Therapeutic Areas